Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.
Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%.
Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program.
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study.
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.
Thiazolidinediones for initial treatment of type 2 diabetes?
Rosiglitazone and cardiotoxicity--weighing the evidence.
Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Glycemic Reduction Approaches for Treating Diabetes: An Effectiveness Study
11/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?